Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)

Eltrombopag (EPAG), a thrombopoietin receptor agonist (TPO-RA), has shown promising results in severe aplastic anemia (SAA), as a single agent in immunosuppressive therapy (IST)-refractory patients and in treatment-na ïve patients when combined with horse antithymocyte globulin (hATG) and cyclosporine (CsA). hATG is unavailable in most parts of the world and is associated with increased toxicity, especially in patients aged>60 years. Moreover, ∼1/3rd of patients after ATG/CsA are considered refractory.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Phillip Scheinberg, Joan Maier, Ozlem Ocak Arikan, Carlo Finelli, Junho Jang Source Type: research